During 30/06-03/07/2022, the Hellenic Society for the Study of Dermatovenereologic and Allergic Diseases (S.S.D.A.D.) held the 5th Panhellenic Conference at hotel DU LAC, Ioannina, under the title: “Dermatological diseases 2022: Past, present and future”. IASIS PHARMA was present, participating dynamically once more in the field of Dermatology.

Dermatologists who attended the Conference had the chance to visit IASIS PHARMA exhibition stand and received information about two of its major Dermatological products:

Combi®, a combination of fluprednidene + miconazole cream, for the treatment of Inflammatory Dermatomycoses such as Fungal Vaginitis (or Vaginal Candidiasis), but also in Εczema re-infected by fungi. Combi® comes in tubes of 50 g. Each gram of the cream contains 1mg Fluprednidene acetate and 20mg Miconazole nitrate.

Interest was also shown for Modiwart®, with imiquimod as its active ingredient. Modiwart® is an innovative immunomodulator, with the following indications: external genital or anogenital warts (Condylomata Acuminata) in adults, small superficial basal cell carcinomas (sBCCs) and clinically typical actinic keratoses (AKs). Modiwart® is distributed in the form of a cream for topical use in 12 sachets package. Each sachet contains 12,5 mg imiquimod in 250 mg cream (5%).